# Dermaliq Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dermaliq-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Wilmington, US
- Website: www.dermaliq.com
- Total disclosed funding: $15M
- Latest round: Series A (Jan 18, 2022)
- Investors on record: 2

## About

Founded in 2021 and based in Delaware, US, Dermaliq Therapeutics, Inc. is a spin-off from Novaliq GmbH that operates as a pharmaceutical company that develops skincare therapies for patients with skin disease. In January 2022, Frank Löscher was appointed as CEO and president of the company, and Dermaliq Therapeutics, Inc. raised USD 15 million in Series A funding led by 3E Bioventures Capital and Beijing Whale Technology Corporation.

The company develops the next generation of skincare therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The technology is called hyliQ™, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of liquid drug products with cosmetic properties.

The organization plans to use the January 2022 funding for three Phase 1/2a clinical development programs in dermatology.

## Funding rounds

- Series A, Jan 18, 2022, $15M — 3E Bioventures Capital, Beijing Whale Technology Corporation

## Investors

- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- Beijing Whale Technology Corporation — Series A